# Phil Tracy

> Phil Tracy is a Series C investor at Intersouth Partners backing Health Care and Therapeutics. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners)
- Total investments: 4
- Last investment: Nov 2013
- Lead investor: 25%
- Last updated: Aug 2026

Phil Tracy is a Series C investor at Intersouth Partners focused on Health Care and Therapeutics. Phil Tracy joined Intersouth in 1997. His pharmaceutical background provides Intersouth with extensive experience in the healthcare industry. He serves on the boards of directors of two Intersouth portfolio companies and has served as interim CEO of an Intersouth portfolio company.The majority of Phil's career was spent at BurroughsWellcome Co., a major research-based pharmaceutical company with $1.2 billion in sales and 5,000 employees. At Burroughs Wellcome, he served as President and CEO from 1989 until the company's merger with Glaxo in 1995.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 25% |
| Therapeutics | 1 | 25% |
| Biotechnology | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 25% |
| Series D | 1 | 25% |
| Series E | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Argos Therapeutics | Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $17.5M | Series E | Nov 20, 2013 |  |
| Argos Therapeutics | Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $42.5M | Series E | Aug 26, 2013 |  |
| Argos Therapeutics | Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $25M | Series D | Apr 24, 2012 |  |
| Argos Therapeutics | Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $17.1M | Series C | May 20, 2008 |  |

4 of 4 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 2 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 2 deals together
- [The Aurora Funds](https://shizune.co/investors/profile/the-aurora-funds) — VC Fund, 2 deals together
- [TVM Capital](https://shizune.co/investors/profile/tvm-capital) — VC Fund, 2 deals together
- [La Caisse](https://shizune.co/investors/profile/caisse-de-depot-et-placement-du-quebec) — VC Fund, 1 deal together
- [Green Cross](https://shizune.co/investors/profile/green-cross) — VC Fund, 1 deal together

## About Intersouth Partners

VC Fund · Durham, United States

Intersouth Partners is one of the most active and experienced venture funds in the Southeast, having invested in more than 100 private companies over the last three decades. Founded in 1985, Intersouth manages $780 million in seven venture capital limited partnerships, making it the largest venture capital fund in North Carolina and one of thelargest in the Southeast.

5 contacts available at Intersouth Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Dennis Dougherty | Founder & Managing General Partner | https://shizune.co/investors/profile/dennis-dougherty |
| John Glushik | Venture Partner | https://shizune.co/investors/profile/john-glushik |
| Kay Burgess | CFO | https://shizune.co/investors/profile/kay-burgess |
| Mitch Mumma | Managing General Partner | https://shizune.co/investors/profile/mitch-mumma |
| Phil Tracy | Venture Partner | https://shizune.co/investors/profile/phil-tracy |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Phil Tracy invest in?

Phil Tracy invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series C and Series D stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Phil Tracy last invest?

The most recent investment recorded for Phil Tracy closed in Nov 2013. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co